{"id":"epcam","name":"EpCAM","symbol":"EPCAM","route":"/targets/epcam/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11529","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119888","uniprot":"https://www.uniprot.org/uniprotkb/P16422/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P16422","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3580493","open-targets":"https://platform.opentargets.org/target/ENSG00000119888","civic":"https://civicdb.org/genes/4072/summary","oncokb":"https://www.oncokb.org/gene/EPCAM","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EPCAM","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=EPCAM","depmap":"https://depmap.org/portal/gene/EPCAM?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000119888-EPCAM","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4072","omim":"https://www.omim.org/entry/185535"}],"products":[{"id":"catumaxomab","name":"Catumaxomab","status":"approved","modality":"Trifunctional bispecific antibody (EpCAM x CD3, rat-mouse hybrid)","route":"/drugs/catumaxomab/"},{"id":"m701","name":"M701","status":"phase-3","modality":"Bispecific antibody (EpCAM x CD3), intraperitoneal","route":"/drugs/m701/"}],"trials":[{"id":"nct06432296","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","nct":"NCT06432296","phase":"3","status":"active"},{"id":"nct00377429","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","nct":"NCT00377429","phase":"2","status":"completed"},{"id":"nct00563836","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","nct":"NCT00563836","phase":"2","status":"completed"},{"id":"nct00189345","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","nct":"NCT00189345","phase":"2","status":"completed"}],"pathways":[],"companies":["lindis-biotech","wuhan-yzy-biopharma"],"keyPapers":["paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}